In these studies, we (1) define the composition of innate cell subsets isolated from COVID-19+ people and healthy controls by flow cytometry, (2) identify specific gene expression profiles using RT-PCR, and finally (3) activate immune cells ex vivo with PRR agonists to assess IFN production. The gene discussed is IFNA1; the disease is COVID-19.